文献速递肝病消化道肿瘤与早癌

间歇性可检测病毒血症不影响未治疗代偿期肝硬化的预后

Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL.
PubMed 文献 · Am J Gastroenterol · 2022-01-01

本研究纳入来自3家三级医院的567例未治疗代偿期肝硬化患者,其血清HBV-DNA持续<2,000 IU/mL,比较间歇性低水平病毒血症(LLV,至少一次可检测到20-2,000 IU/mL)与持续病毒学应答(MVR,持续<20 IU/mL)的预后。结果显示两组在3、5、7年HCC和肝硬化并发症风险上均无显著差异,LLV并非HCC或并发症的独立危险因素,提示对间歇性LLV患者抗病毒治疗的获益需重新评估。

要点

  • 未治疗代偿期肝硬化伴间歇性LLV与MVR相比,HCC和肝硬化并发症风险无显著差异。
  • LLV组3、5、7年HCC累积风险分别为5.7%、10.7%、17.3%,MVR组为7.2%、15.5%、19.4%(P=0.390)。
  • 多因素分析显示LLV与HCC风险(aHR 1.422,95%CI 0.694-2.913;P=0.336)和并发症风险(aHR 1.816,95%CI 0.843-3.911;P=0.128)均无显著关联。

核心结论

  • 在未治疗的代偿期肝硬化患者中,间歇性LLV与MVR相比不增加疾病进展风险,抗病毒治疗对间歇性LLV的获益需重新评估。

研究设计与样本

  • 多中心回顾性队列研究,纳入3家三级医院的567例未治疗代偿期肝硬化患者,血清HBV-DNA持续<2,000 IU/mL,LLV组391例,MVR组176例。

主要发现

  • LLV组与MVR组3、5、7年HCC累积风险分别为5.7%、10.7%、17.3%与7.2%、15.5%、19.4%(P=0.390)。
  • LLV组与MVR组3、5、7年肝硬化并发症累积风险分别为7.5%、12.8%、13.7%与7.8%、12.3%、14.6%(P=0.880)。
  • 多因素分析中LLV与HCC风险aHR 1.422(95%CI 0.694-2.913;P=0.336)、与并发症风险aHR 1.816(95%CI 0.843-3.911;P=0.128)均无显著关联。
  • 逆概率治疗加权分析显示LLV与HCC风险HR 0.903(95%CI 0.528-1.546;P=0.711)、与并发症风险HR 1.192(95%CI 0.675-2.105;P=0.545)均无显著差异。

关键数值与推荐

  • LLV定义为至少1次可检测到血清HBV-DNA(20-2,000 IU/mL),MVR定义为持续检测不到血清HBV-DNA(<20 IU/mL)。
  • 随访中血清HBV-DNA≥2,000 IU/mL时按指南启动抗病毒治疗。

临床怎么用

  • 对于未治疗代偿期肝硬化且HBV-DNA持续<2,000 IU/mL的患者,间歇性LLV可能不增加疾病进展风险,抗病毒治疗决策应综合评估而非仅依据LLV。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The necessity of antiviral therapy (AVT) for hepatitis B virus (HBV)-infected compensated cirrhosis with low-level viremia (LLV) is controversial. Herein, we evaluated its natural history. METHODS: From 3 tertiary hospitals, we enrolled untreated patients with compensated cirrhosis with persistent serum HBV-DNA levels <2,000 IU/mL; LLV was defined as having at least 1 detectable serum HBV-DNA (20-2,000 IU/mL) episode, whereas maintained virological response (MVR) was defined as having persistently undetectable serum HBV-DNA (<20 IU/mL). When serum HBV-DNA was ≥2,000 IU/mL during follow-up, AVT was administered according to guidelines. Study end points were development of cirrhotic complication event (CCE) or hepatocellular carcinoma (HCC). RESULTS: Among 567 patients analyzed, cumulative HCC risk at 3, 5, and 7 years was comparable between LLV (n = 391) vs MVR (n = 176) groups (5.7%, 10.7%, and 17.3% vs 7.2%, 15.5%, and 19.4%, respectively [P = 0.390]). CCE risk was also comparable between 2 groups (7.5%, 12.8%, and 13.7% vs 7.8%, 12.3%, and 14.6%, respectively [P = 0.880]). By multivariate analysis, LLV (vs MVR) was not associated with HCC or CCE risks, with adjusted hazard ratios of 1.422 (95% confidence interval [CI] 0.694-2.913; P = 0.336) and 1.816 (95% CI: 0.843-3.911; P = 0.128), respectively. Inverse probability of treatment weighting analysis yielded comparable outcomes between 2 groups, regarding HCC and CCE risks with hazard ratios of 0.903 (95% CI: 0.528-1.546; P = 0.711) and 1.192 (95% CI: 0.675-2.105; P = 0.545), respectively. DISCUSSION: Episodic LLV among untreated patients with compensated cirrhosis does not increase the risk of disease progression compared with MVR status. Thus, the benefits of AVT for episodic LLV should be re-evaluated.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Lee HW, Park SY, Lee YR, et al. Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL. Am J Gastroenterol. 2022. PMID: 34506308. doi:10.14309/ajg.0000000000001497

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。